Serum Levels of N- and C-ERC/Mesothelin and Clinicopathological Factors in Mesothelioma Patients and Those without Mesothelioma-Reference-Cited by-同舟云学术

Serum Levels of N- and C-ERC/Mesothelin and Clinicopathological Factors in Mesothelioma Patients and Those without Mesothelioma

Published:2023 Issue:2 Volume:69 Page:124-136
ISSN:2187-9737
Container-title:Juntendo Medical Journal
language:en
Short-container-title:Juntendo Medical Journal

Author:

KOYANAGI AI¹,KAJINO KAZUNORI¹^ORCID,NOJIRI SHUKO²,ABE MASAAKI¹,KOBAYASHI TOSHIYUKI¹,SUGITANI YOSHINOBU¹,YUE LIANG¹,OHTSUJI NAOMI³,ARAKAWA ATSUSHI³,SATO TADASHI⁴,TAKAHASHI KAZUHISA⁴,SUZUKI KENJI⁵,ORIMO AKIRA¹,YAO TAKASHI³,HINO OKIO¹

Affiliation:

1. Department of Pathology and Oncology, Juntendo University Graduate School of Medicine

2. Medical Technology Innovation Center, Juntendo University Graduate School of Medicine

3. Department of Human Pathology, Juntendo University Graduate School of Medicine

4. Department of Respiratory Medicine, Juntendo University Graduate School of Medicine

5. Department of General Thoracic Surgery, Juntendo University Graduate School of Medicine

Publisher

The Jutendo Medical Journal

Subject

General Agricultural and Biological Sciences

Link

https://www.jstage.jst.go.jp/article/jmj/69/2/69_JMJ22-0042-OA/_pdf

Reference29 articles.

1. [1] Robinson BWS, Lake RA: Advances in malignant mesothelioma. N Engl J Med, 2005; 353: 1591-1603.

2. [2] Alley EW, Lopez J, Santoro A, et al: Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol, 2017; 18: 623-630.

3. [3] Okada M, Kijima T, Aoe K, et al: Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT). Clin Cancer Res, 2019; 25: 5485-5492.

4. [4] Hino O, Kobayashi E, Nishizawa M, et al: Renal carcinogenesis in the Eker rat. J Cancer Res Clin Oncol, 1995; 121: 602-605.

5. [5] Yamashita Y, Yokoyama M, Kobayashi E, Takai S, Hino O: Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem Biophys Res Commun, 2000; 275: 134-140.